Protheragen, an ISO9001-certified provider of pre-clinical contract research and analytical services, has announced a comprehensive suite of drug analysis solutions designed to support pharmaceutical development from early stages through regulatory submission and commercialization. The integrated offerings include stability testing, impurity testing, and chemical-physical testing, addressing critical quality and safety requirements for drug products.
According to the company, pharmaceutical companies face rigorous testing demands to ensure product safety, efficacy, and compliance with regulatory standards. Protheragen's integrated approach combines stability studies and impurity evaluations to streamline drug development and strengthen quality assurance. The chemical-physical tests cover parameters such as relative density, melting point, optical rotation, viscosity, particle size and morphology, dissolution, disintegration, and oxygen/water vapor transmission rates (OTR & WVTR). These analyses aim to optimize drug formulation, compatibility, and bioavailability while providing insights into product performance under real-world conditions.
The impurity testing service targets a broad range of contaminants, including organic, inorganic, heavy metal, elemental, residual solvent, and genotoxic impurities. By addressing risks from manufacturing byproducts, environmental exposure, and degradation processes, the service helps uphold product purity and safety. Protheragen's stability testing portfolio includes accelerated stability studies, which use elevated temperature and humidity to predict degradation pathways and shelf life, as well as real-time stability studies conducted over the recommended product lifespan. Central to these efforts are forced degradation studies, a critical component of drug development and regulatory compliance. By exposing drug substances and formulations to extreme stressors—such as heat (dry and wet), light (per ICH Guide Option 2), humidity, acid/base hydrolysis, and oxidation—the company identifies intrinsic stability characteristics and degradation pathways. Advanced analytical instruments, including LC-MS, GC-MS, NMR, HPLC, and dynamic light scattering (DLS), are used to quantify degradation levels, validate stability-indicating methods, and provide data-driven recommendations for formulation optimization.
Protheragen emphasizes its commitment to technical excellence, regulatory compliance, and client-centricity. The team of experienced scientists adheres to international guidelines, including ICH standards, ensuring studies meet the highest quality and regulatory requirements. With cutting-edge analytical technology and customized study designs tailored to each drug candidate's unique needs, the company delivers accurate, reliable results within agreed timelines, enabling clients to make informed decisions promptly. The transparent service process—from initial consultation and project planning to analysis, reporting, and follow-up support—ensures clients remain fully engaged at every stage.
Pharmaceutical organizations seeking to enhance development workflows, meet regulatory obligations, or optimize product stability are invited to contact Protheragen for tailored solutions. The company promises to respond to inquiries within 2-4 working days.
